SCHEMBL742800

SCHEMBL742800

COC(=O)/C=C(\N)Cc1cc(F)c(F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.41
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
RORC P51449 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DGAT2 Q96PD7 1/20 0.32
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
CYP2D6 P10635 2/20 0.31
DPP8 Q6V1X1 2/20 0.31
DPP9 Q86TI2 2/20 0.31
DPP7 Q9UHL4 2/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP12 P39900 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861837 1.00 DPP4 (0.41) DPP4HDAC1HDAC8RORCSMN1; SMN2
SCHEMBL29738305 1.00 DPP4 (0.41) DPP4HDAC1HDAC8RORCSMN1; SMN2
SCHEMBL440648 0.85 NPSR1 (0.38) DPP4RORCDPP9MMP1MMP2
SCHEMBL409968 0.85 NPSR1 (0.38) DPP4RORCDPP9MMP1MMP2
SCHEMBL30607053 0.85 NPSR1 (0.38) DPP4RORCDPP9MMP1MMP2
SCHEMBL13780810 0.82 DPP4 (0.36) DPP4HDAC1HDAC8RORCCYP2D6
SCHEMBL3801146 0.81 MAPT (0.39) DPP4MMP1MMP2MMP9MMP12
SCHEMBL3801151 0.81 MAPT (0.39) DPP4MMP1MMP2MMP9MMP12
SCHEMBL18752139 0.80 ATM (0.41) SMN1; SMN2PDE4D
SCHEMBL749408 0.80 HDAC1 (0.35) DPP4HDAC1HDAC8RORCDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108598-A1 SITAGLIPTIN SYNTHESIS MYLAN INDIA PRIVATE LIMITED (IN) 2012-05-03 US claimed
EP-2430025-A1 SITAGLIPTIN SYNTHESIS Generics [UK] Limited (GB) 2012-03-21 EP claimed
CN-114644568-B Purification method of sitagliptin intermediate 浙江医药股份有限公司新昌制药厂 2024-07-19 CN disclosed
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2023-06-08 US disclosed
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2023-06-08 US disclosed
CN-113636950-B Preparation method of chiral 4-aryl-beta-amino acid derivative 浙江医药股份有限公司新昌制药厂 2023-01-17 CN disclosed
CN-114644568-A Purification method of sitagliptin intermediate 浙江医药股份有限公司新昌制药厂 2022-06-21 CN disclosed
CN-113636950-A Preparation method of chiral 4-aryl-beta-amino acid derivative 浙江医药股份有限公司新昌制药厂 2021-11-12 CN disclosed
EP-3156391-B1 METHOD FOR PREPARING SITAGLIPTIN INTERMEDIATE VIA ASYMMETRICAL REDUCTION METHOD ZHEJIANG HUAHAI PHARM CO LTD (CN) 2020-09-02 EP disclosed
US-10189760-B2 Method for preparing sitagliptin intermediate via asymmetrical reduction method ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) 2019-01-29 US disclosed
US-9873651-B2 2018-01-23 US disclosed
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DONG-A PHARMACEUTICAL. CO., LTD (KR) 2012-01-19 US disclosed
US-20100280245-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES CHIRAL QUEST, INC. 2010-11-04 US disclosed
US-20100280245-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES CHIRAL QUEST, INC. 2010-11-04 US disclosed
US-20100280245-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES CHIRAL QUEST, INC. 2010-11-04 US disclosed
WO-2010114291-A2 IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 동아제약 주식회사 (KR) 2010-10-07 WO disclosed
WO-2010114292-A2 IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE 동아제약 주식회사 (KR) 2010-10-07 WO disclosed
WO-2010078440-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES CHIRAL QUEST, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174461-A1 METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE ENPEP, BCAT2, BCAT1 DPP4 330/4885HDAC1 3683/4885HDAC8 4221/4885
US-20120016126-A1 METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 DPP4 1/4885HDAC1 2798/4885HDAC8 2991/4885
US-20120016125-A1 METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE DPP4, DPP3, DPP7 DPP4 1/4885HDAC1 2233/4885HDAC8 2819/4885
US-20120108598-A1 SITAGLIPTIN SYNTHESIS DPP4, DPP7, DPP3 DPP4 1/4885HDAC1 3285/4885HDAC8 3312/4885
US-20100280245-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES NR4A3, GRIA3, NR2C2 DPP4 3380/4885HDAC1 601/4885HDAC8 714/4885
US-10189760-B2 Method for preparing sitagliptin intermediate via asymmetrical reduction method DPP4, DPP7, SI DPP4 1/4885HDAC1 695/4885HDAC8 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.